Key facts
- This page summarizes Mark E. Tryniski's Form 4 filing for CONMED Corp (CNMD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2022, 09:22.
Mark E. Tryniski - 01 Jun 2022 Form 4 Insider Report for CONMED Corp (CNMD)
- Reporting relationship
- Director
- Issuer ticker
- CNMD
- Reported as of
- 01 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2022, 09:22:35 UTC
- Prior SEC filing
- 15 Mar 2023
- Next SEC filing
- 09 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- Sarah M Oliker for Mark E. Tryniski by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark E. Tryniski filed Form 4 for CONMED Corp (CNMD) on 03 Jun 2022.
Change
- Previous filing in this sequence was filed on 15 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNMD
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +812
- Change %
- +9.8%
- Price
- $0.000000
- Shares after
- 9,108
- Date
- 01 Jun 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNMD
transaction
Derivative
Rsus (restricted Stock Units)
Options Exercise
- Transaction value
- $0
- Shares
- -812
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 812
- Exercise price
- $0.000000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Mark E. Tryniski is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 100% after a one year period.